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IMMUNOLOGIC AUTOGRAFT ENGINEERING BY MANIPULATION OF
APHERESIS MACHINE COLLECTION SETTINGS
Joao, C.1,2, Porrata, L.F.2, Burgstaler, E.A.2, Nevala, W.2, Uhl, C.2,
Katipamula, R.2, Gastineau, D.A.2, Winters, J.2, Markovic, S.N.2 1.
Portuguese Institute of Oncology, Lisbon, Portugal; 2. Mayo Clinic
College of Medicine, Rochester, MN.
Introduction: Infused autograft absolute lymphocyte count (A-
ALC) is an independent prognostic indicator of survival in patients
undergoing autologous hematopoietic stem cell transplantation
(AHSCT) for non-Hodgkin’s lymphoma (NHL). We previously
demonstrated that different (instrument speciﬁc) apheresis ma-
chine settings calibrated for the purpose of optimal stem cell
collections have a direct impact on A-ALC, which in turn affected
clinical outcome post-AHSCT. Purpose: We present interim re-
sults from an ongoing prospective study in which pheresis settings
of the Baxter Amicus pheresis machine are systematically altered
with the intent of maximal A-ALC collection while preserving
CD34 counts in patients with NHL. Results: To date, we have
available data on 12 patients (5 females). The apheresis settings of
the machines were modiﬁed for one of the apheresis sessions (test)
and compared to a session using conventional settings (control),
using the same patient as his own control. All the patients were
subject to the same stem cell mobilization regimen (Neupogen).
The analysis of the A-ALC was, on average, 2.86 times higher
compared to the control setting (median of 0.40 and 0.14 
109/Kg, respectively, P  .03). Regarding the numbers of lympho-
cyte subsets (CD3, CD4, CD8, CD3/CD16/CD56,
CD20, CD34, CD4/CD45RA, RO, CD8/CD45RA, RO,
and CD4/CD25), the test settings demonstrated graft enrich-
ment 1.6 to 5.7 times relative to control. Table 1 shows the
absolute lymphocyte subsets numbers  109/kg comparing test
versus control settings. All patients engrafted and none developed
side effects during the apheresis procedure. Conclusion: Our
preliminary data suggest that it is feasible to manipulate the
apheresis settings in order to allow a higher A-ALC. The enrich-
ment with naive T cells, memory T cells, and NK cells by manip-
ulating apheresis machine settings may establish a more immuno-
competent autograft to use as an adoptive immunotherapeutic
strategy in AHSCT warrants further studies (Table 1).
Table 1. Autograft Lymphocyte Subset Analysis Comparing
Manipulated (test) vs Control Setting of the Baxter Amicus
Lymphocyte Subset
Test
( 10[9])/kg
Control
( 10[9])/kg
CD3 0.20 0.06
CD4 0.05 0.02
CD8 0.14 0.04
CD16/CD56 0.04 0.02
CD4/CD25 0.20 0.02
CD4/CD45RA 0.014 0.003
CD4/CD45RO 0.019 0.009
CD8/CD45RA 0.048 0.009
CD8/CD45RO 0.007 0.002
CD20 0.044 0.009
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QUANTITATIVELY MONITORING ENGRAFTMENT OF TWO CHILDREN
WITH MIXED UMBILICAL CORD BLOOD TRANSPLANTATION
Chen, D.-P.1, Tseng, C.-P.2, Wang, M.-C.1, Jaing, T.-H.1,
Sun, C.-F.1 1. Chang Gung Memorial Hospital, Taoyuan County,
Taiwan; 2. Chang Gung University, Taoyuan County, Taiwan.
To study the dynamic engraftment during umbilical cord blood
combined transplantation, two children with severe thalassemia
who received two units unrelated umbilical cord blood transplan-
tation were monitored quantitatively by ﬂuorescence labeling poly-
merase chain reaction. The chimeric types of engraftment were
quantitatively evaluated by comparing 15 STR loci of the blood
samples before and after transplantation. The relative level of the
two donors in the engraftment chimerism was determined by
ﬂuorescence scanning of the STR using ABI PRISM 310 DNA
sequencer. Our data revealed that one child with CD34 2.47 
105/kg (donor 1) and CD34 1.75  103/kg (donor 2) transplan-
tation showed a complete one donor type (donor 1) at 14 days after
engraftment. Follow-up survey at 40 days, 66 days, 120 days, and
150 days after transplantation still showed only one donor type,
indicating that the engraftment turned to a single donor type at a
very early stage and sustained in long-term. The other child with
CD34 1.01  105/kg (donor 1) and CD34 1.53  105/kg
(donor 2) transplantation revealed an engraftment chimera consti-
tuted of 7.02% of donor 1 and 92.98% of donor 2 at 16 days after
transplantation. At 45 days after transplantation, the engraftment
chimera constituted of 4.64% of donor 1 and 95.36% of donor 2.
The one with fewer CD34 stem cells was rejected and the one
with more CD34 stem cells was ﬁnally engrafted. This study
implicates that quantitative detection of STR chimera with ﬂuo-
rescence labeling polymerase chain reaction can depict precisely
the engraftment level and the course of umbilical cord blood
combined transplantation. This method thus provides an accurate
and reliable experimental basis for clinical umbilical cord blood
application and donor selection during children transplantation
with mixed umbilical cord blood.
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PEDIATRIC PATIENTS DEMONSTRATE LOW ABSOLUTE PERIPHERAL
BLOOD CD34 CELLS FOR ADEQUATE STEM CELL COLLECTION
Cheerva, A.C.1,2, Breslin, N.1, Monica, H.1, Hubbard, B.1, Renate, W.1
1. Norton Kosair Children’s Hospital, Louisville, KY; 2. University of
Louisville, Louisville, KY.
The peripheral blood CD34 cell concentration was studied as
a guide to the timing of stem cell aphereses in 35 pediatric patients
with various solid tumors and hematologic malignancies. These 35
patients underwent 82 leukaphereses. There was a highly signiﬁ-
cant correlation between the blood CD34 cell count and the
CD34 cell content in the apheresis product of the same day. The
desired yield of 1  106 CD34 cells/kg was harvested in one
apheresis procedure when the blood CD34 cell count was greater
than 9  106 cells/L. An insufﬁcient stem cell harvest was pro-
duced when the blood CD34 cell count was less than 4.5 
106/L. Engraftment of these cells was evaluated and occurred
within 9–17 days in all cases where the apheresis product cells were
utilized. In this pediatric population of patients, the blood CD34
cell count that produces an adequate stem cell collection is lower
than that reported by others. In adult and mostly adult populations,
the CD34 cell count associated with an adequate collection of
peripheral blood CD34 cells is generally reported as greater than
20  106/L. This may reﬂect more brisk mobilization of bone
marrow CD34 cells in the pediatric population versus the adult
patient population. As in other reports, the CD34 cell count is a
good predictor of the CD34 cell content of the apheresis product.
HEMATOPOIESIS/MESENCHYMAL CELLS
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A STROMAL CELL DERIVED FACTOR 1 (SDF-1) AGONIST STIMULATES
NEUTROPHIL MOBILIZATION IN NORMAL HUMANS AFTER SUBCUTA-
NEOUS INJECTION
Wong, D.1, Korz, W.1, Merzouk, A.1, Salari, H.1, Bensinger, W.I.2 1.
Chemokine Therapeutics Corp, Vancouver, BC, Canada; 2. Fred
Hutchinson Cancer Research Center, Seattle, WA.
Stromal cell-derived factor-1 (SDF-1) is key in the proliferation,
homing, engraftment, and expansion of hematopoietic stem cells
and leukocytes. CTCE-0214, a peptide produced by rational drug
design, is an analog of SDF-1 and agonist of the SDF-1 receptor,
CXCR4. In vitro and in vivo models have shown that CTCE-0214
mobilized blood and progenitor cells and enhanced the survival
and expansion of cord blood cells (Letters in Drug Design and
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